Matt Gline, Roivant CEO (John Sciulli/Getty Images for GLG)
Roivant chops sickle cell gene therapy, dermatology drugs to focus on 'higher value projects'
Roivant is sweeping a suite of drugs, including a gene therapy for sickle cell disease already in the clinic, out of its pipeline.
Six programs …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
